The pharmaceuticals and biotechnology sectors are currently facing increasing some time and cost i...

1. Medicine :: Biomarkers in Late Stage Clinical Trials:
Applications, opportunities and activities of leading players |
ArticleBiz.com
The pharmaceuticals and
biotechnology sectors are currently
facing increasing some time and cost
issues related to clinical trials in drug
discovery. The cost of having a new
drug can reach $2 billion; clinical
trials, regulatory approval and
subsequent launch usually takes to a
decade.
Biomarkers reduce the attrition rate
these days stage many studies by
assessing drug potential regarding
efficacy and toxicity at the first stages
of the clinical development. Thus,
biomarkers significantly increase
productivity, lower the fee and
duration with the medical trial, and
help researchers complete drug
development process at a faster pace.
This report reviews various biomarker
technologies and therapy area
applications. Market drivers and
restraints are viewed inside the
context of biomarker activity of
leading innovator companies along
with contract research organizations.
Key popular features of this report
The report analyzes revenues lately
stage biomarker technology and
services in North America, Europe,
Asia and rest with the world.
Provides key market drivers and restraints in the biomarker market.
Covers microarrays, immunoassay, LC/MS and GC/MS, flow cytometry, imaging, PCR and services
Provides patent analysis regarding competitors and geography.

2. Scope of this report
Understand and assess the growth potential of emerging technologies.
Understand biomarker activity in numerous studies of leading market players.
Gain know-how about the relative importance in the biomarker late stage numerous studies
technologies inside next 5 years for investment opportunities.
Learn which therapy areas leading market players inside the late stage biomarker many studies
market.
Determine the collaborations and partnerships of the major market players.
Key Market Issues
The pharmaceutical and biotech sectors are currently facing increasing duration and price the
business of clinical trials in drug discovery.
Funding from government sources like the National Institutes of Health (NIH) have not increased
significantly over the last couple of years.
Late stage failures less difficult more costly than early ones.
The rising requirement for better safety data has put a considerable amount of regulatory and
economic pressure on pharmaceutical companies.
The current average approval rate of cancer drugs will be as low as 5%, even though the
development period can reach 20 years.
More than 50% of numerous studies fail in Phase III as a result of host of reasons, greater disease
complexity, stiffer clinical endpoints, as well as the inability of your data to prove drug effectiveness.
Key findings from this report
The biomarkers in late stage many studies companies are largest in North American and European
region, with Europe having the second largest market.
North America constitutes the major market share with the immunoassay, flow cytometry and
GC/MS and LC/MS having high market growth.
Caprion proteomics, Applied BioSystems, BG Medicine, Covance, Eli Lilly, Pfizer and Astra Zeneca
are some with the major companies engaged in collaborative partnerships in the past several years.
A number of market players have formed strategic alliances for that development and sharing of
technology for biomarker applications within the late stage numerous studies.
Pharmaceutical companies are focusing mainly on cancer biomarkers to be used in late stage (Phase
III and IV) numerous studies.
Key questions answered

3. How is the biomarker late stage numerous studies market segmented and after that growth be to
2014?
What are the major technologies which may have emerged such as microarrays, PCR, LC/MS and
GC/MS?
In which areas are the companies focusing while forming strategic alliances with other industrial
players?
What is the competitive landscape and what is the strategic focus of innovator companies, CROs and
biomarker specialists?
What applications are pharmaceutical companies centering on while conducting late stage
biomarker numerous studies?
Table of Contents
Biomarkers in Late Stage Clinical Trials
Executive summary 12
Market dynamics 12
Biomarker activity at leading pharma companies 13
Applications of biomarkers in numerous studies 13
Biomarker marketplace for late stage numerous studies by tools and services 14
Company profiles 15
Chapter 1 Market dynamics 18
Chapter 2 Biomarker activity at leading pharma companies 40
Chapter 3 Applications of biomarkers in many studies 62
Chapter 4 Biomarker market for late stage clinical trials by tools and services 80
Appendix 147